We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
Read MoreHide Full Article
Key Takeaways
GSK wins Japan orphan drug status for risvutatug rezetecan in small-cell lung cancer.
GSK's phase I ARTEMIS-001 showed durable responses in extensive-stage SCLC patients.
The candidate also holds FDA Breakthrough and EMA PRIME status, supporting accelerated development.
GSK plc (GSK - Free Report) announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate (“ADC”), for the treatment of small-cell lung cancer (SCLC). This designation marks the sixth global regulatory recognition for risvutatug rezetecan.
The ODD is based on positive preliminary data from the phase I ARTEMIS-001 study, which demonstrated durable responses in patients with extensive-stage SCLC (ES-SCLC).
GSK licensed exclusive global rights (excluding the Chinese mainland) to risvutatug rezetecan from Chinese biotech Hansoh Pharma in December 2023.
Over the past year, GSK’s shares have surged 34.4% compared with the industry’s 9.1% growth.
Risvutatug rezetecan has received several other expedited designations to accelerate its development and regulatory review in solid tumors with transformational potential. In December, the FDA granted ODD for the treatment of SCLC, while the European Medicines Agency (EMA) granted ODD in October for the treatment of pulmonary neuroendocrine carcinoma, which includes SCLC.
Previously, the EMA had awarded PRIME designation for relapsed or refractory ES-SCLC. The drug also earned the FDA’s Breakthrough Therapy Designation for relapsed or refractory ES-SCLC and osteosarcoma.
Development Plan for Risvutatug Rezetecan
GSK continues to advance risvutatug rezetecan through late- and mid-stage clinical development. A global phase III study evaluating risvutatug rezetecan in relapsed ES-SCLC began in August 2025 and is ongoing. Another phase III study is evaluating the drug for osteosarcoma, a rare and aggressive bone cancer. Early- to mid-stage studies are underway to assess its potential in several other cancers, such as non-small-cell lung cancer, head and neck cancer, prostate cancer.
Lung cancer remains the second most prevalent cancer in Japan, with SCLC accounting for approximately 10% to 15% of all cases. Among these patients, nearly 70% have extensive-stage disease, characterized by widespread tumor dissemination. Most patients with ES-SCLC relapse after initial treatment, with survival times often measured in months rather than years.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 19.1% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Liquidia Corporation’s 2026 earnings per share have risen from $1.06 to $1.75. LQDA shares have surged 132.5% over the past year.
Liquidia Corporation’s earnings beat estimates in two of the trailing four quarters, while missing in the remaining two, with the average surprise being 39.38%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have rallied 13.1%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
Key Takeaways
GSK plc (GSK - Free Report) announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate (“ADC”), for the treatment of small-cell lung cancer (SCLC). This designation marks the sixth global regulatory recognition for risvutatug rezetecan.
The ODD is based on positive preliminary data from the phase I ARTEMIS-001 study, which demonstrated durable responses in patients with extensive-stage SCLC (ES-SCLC).
GSK licensed exclusive global rights (excluding the Chinese mainland) to risvutatug rezetecan from Chinese biotech Hansoh Pharma in December 2023.
Over the past year, GSK’s shares have surged 34.4% compared with the industry’s 9.1% growth.
Image Source: Zacks Investment Research
GSK’s Risvutatug Rezetecan Wins Multiple Designations
Risvutatug rezetecan has received several other expedited designations to accelerate its development and regulatory review in solid tumors with transformational potential. In December, the FDA granted ODD for the treatment of SCLC, while the European Medicines Agency (EMA) granted ODD in October for the treatment of pulmonary neuroendocrine carcinoma, which includes SCLC.
Previously, the EMA had awarded PRIME designation for relapsed or refractory ES-SCLC. The drug also earned the FDA’s Breakthrough Therapy Designation for relapsed or refractory ES-SCLC and osteosarcoma.
Development Plan for Risvutatug Rezetecan
GSK continues to advance risvutatug rezetecan through late- and mid-stage clinical development. A global phase III study evaluating risvutatug rezetecan in relapsed ES-SCLC began in August 2025 and is ongoing. Another phase III study is evaluating the drug for osteosarcoma, a rare and aggressive bone cancer. Early- to mid-stage studies are underway to assess its potential in several other cancers, such as non-small-cell lung cancer, head and neck cancer, prostate cancer.
Lung cancer remains the second most prevalent cancer in Japan, with SCLC accounting for approximately 10% to 15% of all cases. Among these patients, nearly 70% have extensive-stage disease, characterized by widespread tumor dissemination. Most patients with ES-SCLC relapse after initial treatment, with survival times often measured in months rather than years.
GSK’s Zacks Rank & Stocks to Consider
GSK currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 19.1% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Liquidia Corporation’s 2026 earnings per share have risen from $1.06 to $1.75. LQDA shares have surged 132.5% over the past year.
Liquidia Corporation’s earnings beat estimates in two of the trailing four quarters, while missing in the remaining two, with the average surprise being 39.38%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have rallied 13.1%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.